IL37752A - Imidazo(4,5-b)pyridine-2-carbamic acid derivatives,processes for their preparation and pharmaceutical and veterinary compositions containing the same - Google Patents

Imidazo(4,5-b)pyridine-2-carbamic acid derivatives,processes for their preparation and pharmaceutical and veterinary compositions containing the same

Info

Publication number
IL37752A
IL37752A IL37752A IL3775271A IL37752A IL 37752 A IL37752 A IL 37752A IL 37752 A IL37752 A IL 37752A IL 3775271 A IL3775271 A IL 3775271A IL 37752 A IL37752 A IL 37752A
Authority
IL
Israel
Prior art keywords
imidazo
general formula
pyridine
preparation
quaternary ammonium
Prior art date
Application number
IL37752A
Other versions
IL37752A0 (en
Original Assignee
Rhone Poulenc Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7034133A external-priority patent/FR2105060A1/en
Priority claimed from FR7130825A external-priority patent/FR2150236A2/en
Application filed by Rhone Poulenc Sa filed Critical Rhone Poulenc Sa
Publication of IL37752A0 publication Critical patent/IL37752A0/en
Publication of IL37752A publication Critical patent/IL37752A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

IMIDAZO[U,5-fcJPYRIDINE-2-CARBAMIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING THE SAME.
THIS INVENTION relates to new therapeutically useful imidazo [4-,5-b ]pyridine derivatives and acid addition and quaternary ammonium salts thereof, to processes for their preparation and pharmaceutical compositions containing them.
The new imidazo[4,5-b ]pyridine derivatives of the present invention are those of the general formula: H wherein R represents a hydrogen atom or an:alkyl radical containing 1 to carbon atoms , R1 represents a hydrogen atom^ or qn According to a feature of the invention, the compounds of general formula I wherein ^ represents a hydrogen atom are prepared by the process which comprises reacting a diaminopyridine of the general formula: (wherein R is hereinbefore defined) with an isothiourea of the general formula:- R 0C0-N=C-NH-C00R d \ ^ III SCH3 wherein 1L, is as hereinbefore defined. The reaction is generally carried out in an aqueous acid medium, e.g. aqueous acetic acid, at a temperature between 50° and 100°C.
The diaminopyridines of general formula II can be prepared according to the method of Lapin and Slezak, J. Amer. Chem. Soc, 2» 2806 (1950), by reduction of the corresponding 2-amino-3-nitropyridines, which themselves can be prepared by the method of Pino and Zehrung, J. Amer. Chem. Soc, 2Z» 3154- (1955) # The diaminopyridines of general formula II can also be prepared by the method of Graboyes and Day, J. Amer, Chem, Soc, 22* 6 *"21 (1957) .
The isothioureas of general formula III can be obtained by reaction of an alkyl halogenoformate of the general formula: Hal - C00R2 IV (wherein Hal represents a halogen atom and is as hereinbefore defined) with 2-methylisothiourea.
According to a further feature of the invention, the compounds of general formula I wherein R-^ represents a hydrogen atom are prepared by the process which comprises the cyclisation by heating of a pyridine derivative of the general formula: wherein R^ represents a hydrogen atom or a grouping -CS-NH-C00R2, and R and ≥ are as hereinbefore defined. The reaction is generally carried out in an acid medium, such as acetic acid in water, and in the presence of a copper salt, e.g. cuprous acetate, and advantageously at the reflux temperature of the reaction mixture.
The pyridine derivatives of general formula V can he obtained by reaction of an isothiocyanate of the general formula: S=C=N-C00R2 VI (wherein Rg is as hereinbefore defined) with a diamino- pyridine of general formula II. The reaction can generally be carried out in an inert organic solvent at a temperature of about 25°G.
According to another feature of the invention, the compounds of general formula I wherein represents a hydrogen atom er an alkyl radical containing- 1 to - oarbon atomo are prepared by the process which comprises reacting a cyanamide of the general formula: Rj-HH-CN" VII (wherein ^ is as hereinbefore defined) with an alkyl halogenoformate of general formula IV, and reacting the resulting compound of the general formula: R, -N-CN I VIII C00R2 (wherein 1 and ≥ are as hereinbefore defined) with a diaminopyridine of general formula II. The reactions can generally be carried out in an inert organic solvent and at a temperature between 0° and 50°C.
The imidazole,5-b]pyridine derivatives of general formula I obtained by the aforementioned processes can be purified by physical methods such as distillation, crystallisation or chromatography, or by chemical methods such as the formation of salts, crystallisation of the salts and decomposition of them in an alkaline medium. In carrying out the said chemical methods the nature of the anion of the salt is immaterial, the only requirement being that the salt be well-defined and readily crystallisable .
The imidazo[4,5-b]pyridine derivatives of general formula I may be converted by methods known per se into acid addition and quaternary ammonium salts. The acid addition salts may be obtained by the action of acids on the imidazo [4-,5-b ]pyridine derivatives in appropriate solvents. As organic solvents there may be used alcohols, ketones, ethers or chlorinated hydrocarbons. The salt which is formed is precipitated, if necessary after concentration of the solution, and is isolated by filtration or decantation. The quaternary ammonium salts may be obtained by the action of esters on the imidazo 4,5-b1}pyridine bases, optionally in an organic solvent, at room temperature or, more rapidly, with gentle heating.
The imidazo[-,5-b]pyridine derivatives of the present invention, and their acid addition and quaternary ammonium salts, possess useful anthelmintic properties associated with a low toxicity. (The imidazo[4-,5-b]-pyridine derivatives conforming to general formula I obtained as products in the following Examples are all atoxic to mice at 1 g./kg. animal body weight when administered orally). They have shown themselves 4 particularly active against experimental infestations in mice of Nippostrongylus mu is and Nematospi oides dubius at doses of between 200 and 1,000 mg./kg. animal body weight when administered orally, in dogs of Ankylostoma caninum, Uhcinaria stenocephala, Toxocara canis, Toxascaris leonina, Trichuris vu pis, Taenia sj>. and.
Dipylidium caninum at doses of between 15 and 150 mg./kg. animal body weight when administered orally, and in sheep of Haemonchus contortus, Trichostrongylus axei, Ostertagia circumcincta, Trichostrongylus colubriformis , Nematodirus battus and Dictyocaulus filaria at doses of between 15 and 100 mg./kg. animal body weight when administered orally. Generally, two administrations of the compounds, the second six hours after the first, are effective in counteracting the helminth infestation* In vitro, the compounds have shown activity against larvae of digestive threadworms of horses.
Preferred compounds of the invention are those wherein 3¾^ in general formula I repreconte a hydrogen atom, and, ma-ge,..especially those compounds- whereas, H and R-j. represent hydrogen atoms and Eg represents a methyl. or ethyl radical, i.e. 2-methoxycarbonylamino-imidazo[il-,5-b]-pyridine and 2-ethoxyc3Q?bonylamino-imidazo[4-,5-b3pyridine, and acid addition and quaternary ammonium salts thereof.
For therapeutic purposes, the imidazo[ , 5-bJ-pyridine derivatives of general formula I may be employed as such or in the form of non-toxic acid addition salts, i.e. salts containing anions which are relatively innocuous to the animal organism in therapeutic doses of the salts (such as hydrochlorides, sulphates, nitrates, phosphates, acetates, propionates, succinates, benzoates, fumarates, maleates, tartrates, theophyllineacetates, salicylates, phenolphthalinates and methylene-bis-β-hydroxynaphthoates) so that the beneficial physiological properties inherent in the bases are not vitiated by side-effects ascribable to the anions. However, they may also be employed in the form of non-toxic quaternary ammonium salts obtained by reaction with organic halides, e.g. methyl, ethyl, allyl or benzyl chloride, bromide or iodide, or other reactive esters, e.g. methyl- or ethyl-sulphates, benzene-sulphonates or toluene-£-sulphonates.
The following Examples illustrate the invention.
EXAMPIJE 1 2, 3-Diaminopyridine (21.8 g.) is added to a suspension of l, 3-^-^thoxycarbonyl-2-methylisothiourea (46.8 g.) in water (200 cc.) and acetic acid (J6 g.), and the mixture is heated at 80-90°C. until the evolution of gas ceases. After cooling, the precipitate which appears is filtered off, washed with acetone (3 x 50 cc.) and taken up in N hydrochloric acid (200 cc). The hydrochloric acid solution obtained after filtration is neutralised by the addition of solid potassium bicarbonate (20 g.). The precipitate which appears is filtered off and dried under reduced pressure (0.5 mm.Hg.) at 20°C. to yield 2-ethoxycarbonylamino-imidazo['4-, 5-b]pyridine (22.7 g.) melting at 285°C. with decomposition. 2, 3-Diaminopyridine, melting at 115-116°C, employed as starting material can be prepared from 2-amino- pyridine according to the method described in Org. Synth, 44-, 34 (1964). (bis The 1 , 3--Q¾etho3iycarbonyl)-2-methylisothiourea, melting at 46°C., can be obtained by the action of ethyl chloroformate on 2-methylisothiourea.
EXAMPLE 2 A mixture of 1 , 3^t£aethoxycarbonyl '2-methyl-isothiourea (22.3 g.), 2, 3-diaminopyridine (11.8 g.) in water (108 cc.) and acetic acid (19»4- g.) is heated at 90-95°C. until the evolution of gas ceases. The reaction mixture is then treated as described in Example 1 to yield 2-methoxycarbonylamino-imidazo[4, 5-b]pyridine (10.9 g«) melting at 305-307°C with decomposition.
Qis 1 , 3-S^me'fchoxycarbony-l)-2-methylisothiourea, melting at 100°C, employed as starting material can be obtained by the action of methyl chloroformate on 2-methylisothiourea. (12.5 g») is added, with agitation, to a suspension of 2, 3-aHamino-6-me hylpyridine ( 7cA3 g.) in distilled water (60 cc.) and acetic acid. (10.9 g.)} and the mixture is heated at 81°C. for hours. After cooling, the suspension obtained is filtered and the resulting solid is washed with distilled water (4 x 10 cc.) and then with acetone (2 x 10 cc). The product obtained (7.6 g.) is dissolved in N hydrochloric acid (41 cc). After treatment with decolourising charcoal, the solution obtained is filtered and to the filtrate is added a solution of sodium bicarDonate (3.5 g») in"water (35 cc). The solid which appears is filtered off, washed with distilled water (5 x 10 cc.) and then with acetone (2 x 20 cc.) to yield 2-methoxycarbonylamino-5-methyl-imidazo[ ,5-h]pyridine (7 g.) melting at 271-272°C.
EXAMPLE 4- 1,3-¾¾jnethoxycarbony])-2-iiaethylisothiourea (26.5 g.) is added, with agitation, to a suspension of 2,3-diamino-5-methylpyridine (15.7 g») in distilled water (128 cc.) and acetic acid (23 g.), and the mixture is heated at 90°C. for 3 hours. After cooling, the suspension obtained is filtered, the resulting solid washed with distilled water ( x 30 cc.) and then with acetone (2 x 30 cc). The product obtained (11*7 g») is dissolved in acetic acid (60 cc.) under reflux. After treatment with decolourising charcoal, the resulting solution is. filtered and, on cooling the filtrate, a solid appears and is filtered off, washed with acetic acid (2 x 5 cc.) and then with anaesthetic grade diethyl ether (3 x 20 cc.) to yield 2-methoxycarbonylamino-6- methyl-imidazo[ , 5-b]pyridine (9·3 g«) decomposing at 36 -368°C. before melting.
EXAMPLE 5 A suspension of 2-(3~methoxycarbonyl-thioureido)- 25 3-aminopyridine (2.26 g.) and cuprous acetate (2 g.) in water (20 cc.) and acetic acid (20 cc.) is heated at 102°C. for 5 hours. The suspension obtained is then filtered and I the filtrate made alkaline by the addition of ammonium I hydroxide solution (d = 0.92) until the pH is 8. A solid J. appears which is filtered off, washed x^ith distilled water (3 x 5 cc.) to yield 2-methoxycarbonylamino-imidazo[ ,5-bJpyridine (0.6 g.) melting at 285-290°C. 2-(3-Methoxycarbonyl-thioureido)-3-aminopyridine (15*5 g.), which decomposes at 230°C, employed as starting material can be prepared by reacting methyl isothiocyanato-formate (15.2 g.) with 2, 3-diaminopyridine (28.4 g.) in acetonitrile (370 cc.) at 25°C.
The present invention also includes pharmaceutica an veterinary compositions which comprise, as the active ingredient, at least one imidazole, 5-b]pyridine derivative of general formula I, or a non-toxic acid addition or quaternary ammonium salt thereof, in association with a carrier or coating generally used in the preparation of pharmaceutical and veterinary compositions.. The compositions are preferably in a form suitable for oral administration.
Tablets, pills, powders, or granules can be used as solid compositions for oral administration. In these compositions the imidazo[ , 5-b]pyridine compound is mixed with one or more inert diluents, such as sucrose, lactose or starch. These compositions can also contain substances other than diluents, for example lubricants such as magnesium stearate.
Pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs, containing inert diluents such as water or pa-raffin oil, can be used as liquid compositions for oral administration. These compositions can also contain substances other than the diluents, such as for example, wetting agents, or sweetening, flavouring or aromatizing agents.
In veterinary therapy, the imidazo[4-, 5-¾]pyridine derivatives can be used for the treatment of cestodal or nematodal helminthiases of cattle, sheep, goats, dogs and domestic animals in general, at single dosages of between 15 and 150 mg./kg. animal body weight, administered orally.
In human therapy, the imidazo[4-, 5-b]pyridine derivatives can be used to eliminate eelworms and cestodes at single dosages of between 10 and 50 mg./kg. administered orally. These dosages can be repeated at regular intervals of several days or several weeks to achieve definitive removal of the parasite.
In general, the physician or veterinary surgeon will decide the posology which is considered most appropriate, depending on the species in question as well as the age, the weight, the degree of infection and all other factors peculiar to the subject to be treated.
The following Example illustrates therapeutic compositions according to the invention.
EXAMPLE 6 Tablets, weighing 0.7 g», having the following composition are prepared in accordance with the usual technique: 2-methoxycarbonylamino-imidazo[ , -b]pyridine 0.500 g. wheat starch 0.150 g. colloidal silica 0.040 g. magnesium stearate 0.010 g.

Claims (20)

WE CLAIM
1. Imidazo[4,5- ]pyridine derivatives of the general formula: H wherein R represents a hydrogen atom or an alkyl radical containing 1 to carbon atoms, R^ represents a hydrogen atom, or an ο,-Usyj r-adical containing; 1 to 4 caxhom atoms, and 2 represents an alkyl radical containing 1 to carbon atoms, and acid addition and quaternary ammonium salts thereof.
2. Imidazo[4,5-b Jpyridine compounds according to claim 1 wherein R^ represents a- hydrogen atom and -^ and R are as defined in claim 1.
3. Imidazo[ ,5-b]pyridine compounds according claim 1 wherein R and -^ represent hydrogen atoms and 2 is as defined in claim 1.
4. 2-Methoxycarbonylamino-imidazp[ ,5-b]pyridine and acid addition and quaternary ammonium salts thereof.
5. 2-Ethoxycarbonylamino-imidazo[ ,5-b]pyridine and acid addition and quaternary ammonium salts thereof.
6. 2-Metho.^carbonylamino-5-methyl-imidazo- [4,5-bJpyridine and acid addition and quaternary ammonium salts thereof.
7. 2-Metho2qrcarbonylamino-6-methyl-imidazo- salts thereof.
8. -Process for the preparation of imidazo-[ , 5-h]pyi'idine derivatives of the general formula specified in claim 1 wherein represents a hydrogen atom which comprises reacting a diaminopyridine of the general formul : (wherein R is as defined in claim 1) with an isothiourea of the general formula: R20C0-N=C- i-C00R2 SCH5 wherein R2 is as defined in claim 1.
9. Process according to claim 8 in which the reaction is carried out in an aqueous acid medium at a temperature "between 50° and 100°C.
10. Process for the preparation of imidazo-[4,5-¾]pyridine derivatives of the general formula specified in claim 1 wherein R^ represents a hydrogen atom which comprises cyclising "by heating a pyridine derivative of the general formula: wherein R-j represents a hydrogen atom or a grouping ~CS-NH-C00R2, and R and R2 are as defined in claim 1.
11. Process according to claim 10 in which cyclisation of the pyridine derivative is carried out in an acid medium and in the presence of a copper salt.
12. Process according to claim 10 or 11 in which cyclisation of the pyridine derivative is carried out in aqueous acetic acid in the presence of cuprous acetate.
13. Process for the preparation of imidazole, 5-h]pyridine derivatives as claimed in claim 1 which comprises reacting a cyanamide of the general formula: R1-NH-CN (wherein is as defined in claim 1) with an alkyl halogenoformate of the general formula: Hal-C00R2 (wherein Hal represents a halogen atom and R2 is as defined in claim 1), and the resulting compound of the general formula: R^-N-CN C00R2 is reacted with a diaminopyridine of the general formula specified in claim 8.
14. ·* Process according to claim 13 wherein the reactions are carried out in an inert organic solvent and at a temperature "between 0° and 50°C.
15. Process according to any one of claims 8 to 1 followed by the step of converting by methods known per so an imidazo[4-, 5-b]pyridine "base thus obtained into an acid addition or quaternary ammonium salt.
16. Process for the preparation of imidazole, 5-b]pyridine derivatives of the general formula specified in claim 1 substantially as described in Example 1 or 2.
17. Process for the preparation of imidazo[ , 5-bJ_~ pyridine derivatives of the general formula specified in claim 1 substantially as described in Example 3, · or 5.
18. Imidazo[ ,5-b]pyridine derivatives of the general formula specified in claim 1 and acid addition and quaternary ammonium salts thereof when prepared by the process claimed in any one of claims 8 to 17.
19. · Pharmaceutical and veterinary compositions which comprise, as active ingredient, at least one imidazo-[4, 5~b]pyridine derivative as claimed in any one of claims. 1 to 7, or a non-toxic acid addition or quaternary ammonium salt thereof, in association with a carrier or coating used in the preparation of pharmaceutical and veterinary compositions.
20. Pharmaceutical compositions according to claim 19 substantially as hereinbefore described with especial reference to Example 6.
IL37752A 1970-09-21 1971-09-17 Imidazo(4,5-b)pyridine-2-carbamic acid derivatives,processes for their preparation and pharmaceutical and veterinary compositions containing the same IL37752A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7034133A FR2105060A1 (en) 1970-09-21 1970-09-21 Anthelmintic imidazo (4,5-b) pyridine derivs - with low mammalian toxicity,for oral human and veterinary use
FR7130825A FR2150236A2 (en) 1971-08-25 1971-08-25 Anthelmintic imidazo (4,5-b) pyridine derivs - with low mammalian toxicity,for oral human and veterinary use

Publications (2)

Publication Number Publication Date
IL37752A0 IL37752A0 (en) 1971-11-29
IL37752A true IL37752A (en) 1974-10-22

Family

ID=26215952

Family Applications (1)

Application Number Title Priority Date Filing Date
IL37752A IL37752A (en) 1970-09-21 1971-09-17 Imidazo(4,5-b)pyridine-2-carbamic acid derivatives,processes for their preparation and pharmaceutical and veterinary compositions containing the same

Country Status (13)

Country Link
AU (1) AU453067B2 (en)
BE (1) BE772835A (en)
CA (1) CA940131A (en)
CH (1) CH532600A (en)
DE (1) DE2147103C3 (en)
DK (1) DK131345B (en)
ES (2) ES395260A1 (en)
GB (1) GB1318859A (en)
HU (1) HU163150B (en)
IL (1) IL37752A (en)
LU (1) LU63927A1 (en)
NL (1) NL145553B (en)
SE (1) SE368828B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002540151A (en) 1999-03-31 2002-11-26 ザ プロクター アンド ギャンブル カンパニー Virus treatment
US6593466B1 (en) * 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment

Also Published As

Publication number Publication date
HU163150B (en) 1973-06-28
ES395260A1 (en) 1973-12-01
IL37752A0 (en) 1971-11-29
NL145553B (en) 1975-04-15
AU3373571A (en) 1973-03-29
DE2147103A1 (en) 1972-03-23
DK131345B (en) 1975-06-30
DE2147103C3 (en) 1975-07-17
GB1318859A (en) 1973-05-31
SE368828B (en) 1974-07-22
DE2147103B2 (en) 1974-11-14
NL7112971A (en) 1972-03-23
LU63927A1 (en) 1972-06-27
CH532600A (en) 1973-01-15
ES403910A1 (en) 1975-05-01
CA940131A (en) 1974-01-15
BE772835A (en) 1972-03-20
DK131345C (en) 1975-11-24
AU453067B2 (en) 1974-09-19

Similar Documents

Publication Publication Date Title
US5260291A (en) Tetrazine derivatives
EP0150255B1 (en) Pyrrolo[1,2-a]imidazole and imidazo[1,2-a]pyridine immunomodulators
RU2136682C1 (en) Imidazopyridines, method of their synthesis, pharmaceutical composition on said and method of pharmaceutical composition preparing
CZ301499A3 (en) Compounds for inhibiting secretion of bile acid
DK161147B (en) METHOD OF ANALOGY FOR THE PREPARATION OF OE3HAA-IMIDAZO-OE5,1-DAA-1,2,3,5-TETRAZIN-4-UNDIVERIVES
EP0449726B1 (en) Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient
EP0470006B1 (en) Thiourea derivatives and antimicrobial agent and antiulcer agent containing the same
US4232161A (en) 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4234725A (en) 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4261928A (en) 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
EP0237289A2 (en) Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
GB1604163A (en) 5(6)-thio-substituted-benzimidazole-2-amines and n-alkoxycarbonyl derivatives thereof and precursors therefor all having physiological activity
EP0171739B1 (en) Imidazo[1,5-a]pyrimidine derivatives and process for their preparation
US3759938A (en) Thiazolidine derivatives
SU1487813A3 (en) Method of producing penem compounds
IL37752A (en) Imidazo(4,5-b)pyridine-2-carbamic acid derivatives,processes for their preparation and pharmaceutical and veterinary compositions containing the same
JP2632248B2 (en) 4-hydroxycoumarin derivative having antibacterial activity
US5214053A (en) Thiourea derivatives and antimicrobial agent and antiulcer agent containing the same
US3984549A (en) Substituted pyrido-triazines as anthelmintics
US3954784A (en) Imidazo[2,1-b]thiazole and thiazolo[3,2-a]-benzimidazole quaternary salts as hypoglycemic agents and growth promotants
EP0224121A2 (en) 7-[4-amino-piperazinyl]- or 7-[4-chloro-piperazinyl]quinolinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
EP0105912B1 (en) Improved melaminylthioarsenites
US3801583A (en) Derivatives of 2-mercapto-pyrido(1,2-b)-1,2,4-thiadiazolium salts
US3980796A (en) Substituted 2-alkoxycarbonylamine-5-(6)-phenylmercapto-benzimidazoles
Patwardhan et al. Structure-activity correlations of cytochalasins. Novel halogenated and related cytochalasin C and D derivatives